Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 10-14

  Na, Kuk Young ^a   Kim, Ra Mi ^a   Song, Eun Mi ^a   Lee, Ji Hyun ^a   Lee, Jandee ^a   Soh, Euy Young ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

BRAF mutation; Familial non medullary thyroid cancer; Loss of heterozygosity; RAS mutation; Susceptibility loci

Indexed keywords

B RAF KINASE; MNG1 PROTEIN; NMTC PROTEIN; PROTEIN; PTC PRN PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CODON; FAMILIAL CANCER; FAMILIAL NON MEDULLARY THYROID CANCER; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NON MEDULLARY THYROID CANCER; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; DNA, NEOPLASM; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; THYROID NEOPLASMS;

EID: 83555164987     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22064     Document Type: Article

References (28)

1. Korea KCCRMoHaWRo: Annual Report of the Central Cancer Registry in Korea. InSeoul: Korea Central Cancer Registry Ministry of Health and Welfare Republic of Korea, 2007, 1-114.
2. Malchoff CD, Malchoff DM,: Familial nonmedullary thyroid carcinoma. Cancer Control 2006; 13: 106-110.
3. Malchoff CD, Malchoff DM,: The genetics of hereditary nonmedullary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 2455-2459. (Pubitemid 34655300)
4. Uchino S, Noguchi S, Kawamoto H, et al.: Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002; 26: 897-902. (Pubitemid 36920283)
5. Burgess JR, Duffield A, Wilkinson SJ, et al.: Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab 1997; 82: 345-348. (Pubitemid 27068589)
6. Grossman RF, Tu SH, Duh QY, et al.: Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995; 130: 892-897 (discussion 898-899).
7. Musholt TJ, Musholt PB, Petrich T, et al.: Familial papillary thyroid carcinoma: Genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 2000; 24: 1409-1417.
8. Bignell GR, Canzian F, Shayeghi M, et al.: Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997; 61: 1123-1130. (Pubitemid 27492321)
9. Canzian F, Amati P, Harach HR, et al.: A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998; 63: 1743-1748. (Pubitemid 30415737)
10. Malchoff CD, Sarfarazi M, Tendler B, et al.: Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000; 85: 1758-1764. (Pubitemid 32269272)
11. McKay JD, Lesueur F, Jonard L, et al.: Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001; 69: 440-446. (Pubitemid 32695216)
12. Frattini M, Ferrario C, Bressan P, et al.: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436-7440. (Pubitemid 39382146)
13. Hou P, Xing M,: Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer. Cell Cycle 2006; 5: 2036-2039. (Pubitemid 44435312)
14. Cavaco BM, Batista PF, Martins C, et al.: Familial non-medullary thyroid carcinoma (FNMTC): Analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer 2008; 15: 207-215. (Pubitemid 351449740)
15. Canzian F, Salovaara R, Hemminki A, et al.: Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996; 56: 3331-3337. (Pubitemid 26242985)
16. Triponez F, Wong M, Sturgeon C, et al.: Does familial non-medullary thyroid cancer adversely affect survival? World J Surg 2006; 30: 787-793. (Pubitemid 43724107)
17. Loh KC,: Familial nonmedullary thyroid carcinoma: A meta-review of case series. Thyroid 1997; 7: 107-113.
18. Xing M,: BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262. (Pubitemid 40896444)
19. Park KY, Koh JM, Kim YI, et al.: Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf) 1998; 49: 317-323. (Pubitemid 28448941)
20. Vasko V, Ferrand M, Di Cristofaro J, et al.: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-2752. (Pubitemid 36724451)
21. Kim YC, Park KO, Kern JA, et al.: The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22: 181-190. (Pubitemid 29067392)
22. Oliveira C, Westra JL, Arango D, et al.: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-2311. (Pubitemid 39359927)
23. Neumann S, Willgerodt H, Ackermann F, et al.: Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 1999; 84: 3750-3756. (Pubitemid 30645236)
24. Bevan S, Pal T, Greenberg CR, et al.: A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: Confirmation of linkage to TCO1. J Clin Endocrinol Metab 2001; 86: 3701-3704. (Pubitemid 32755963)
25. McKay JD, Thompson D, Lesueur F, et al.: Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer. J Med Genet 2004; 41: 407-412. (Pubitemid 38788034)
26. Prazeres HJ, Rodrigues F, Soares P, et al.: Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Fam Cancer 2008; 7: 141-149. (Pubitemid 351871906)
27. Stankov K, Pastore A, Toschi L, et al.: Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. Int J Cancer 2004; 111: 463-467. (Pubitemid 38998831)
28. Park WS, Vortmeyer AO, Pack S, et al.: Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29: 127-130. (Pubitemid 28099506)